← 返回

关注 CD8(+) T 细胞表型:改善实体瘤治疗

英文原题:Focusing on CD8(+) T-cell phenotypes: improving solid tumor therapy.

查看英文原题

Focusing on CD8(+) T-cell phenotypes: improving solid tumor therapy.

PubMed 2024/09/28(内容时间) J Exp Clin Cancer Res Q1 · IF 14.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

强效的CD8+ T细胞在识别肿瘤细胞和对抗实体瘤中发挥着至关重要的作用。T细胞如何有效识别和靶向肿瘤抗原,以及如何在“排斥”实体瘤微环境中维持活性,是主要关注点。近期对CD8+T细胞免疫轨迹和寿命的理解进展,为设计更优化的抗肿瘤免疫治疗方案提供了指导。在此,我们综述了新发现的增强CD8+T细胞对抗实体瘤功能的方法,重点关注优化T细胞受体(TCR)表达、改善工程化T细胞的抗原识别、增强TCR-CD3复合物的信号转导、诱导多克隆功能性T细胞向肿瘤归巢、逆转慢性抗原刺激下的T细胞耗竭,以及重编程T细胞的能量和代谢途径。我们还讨论了如何参与CD8+T细胞的表观遗传改变,以调控抗肿瘤应答的两个关键指标,即有效性和持久性。

展开英文摘要原文

Vigorous CD8 + T cells play a crucial role in recognizing tumor cells and combating solid tumors. How T cells efficiently recognize and target tumor antigens, and how they maintain the activity in the "rejection" of solid tumor microenvironment, are major concerns. Recent advances in understanding of the immunological trajectory and lifespan of CD8 + T cells have provided guidance for the design of more optimal anti-tumor immunotherapy regimens.

Here, we review the newly discovered methods to enhance the function of CD8 + T cells against solid tumors, focusing on optimizing T cell receptor (TCR) expression, improving antigen recognition by engineered T cells, enhancing signal transduction of the TCR-CD3 complex, inducing the homing of polyclonal functional T cells to tumors, reversing T cell exhaustion under chronic antigen stimulation, and reprogramming the energy and metabolic pathways of T cells.

We also discuss how to participate in the epigenetic changes of CD8 + T cells to regulate two key indicators of anti-tumor responses, namely effectiveness and persistence.

论文信息

作者
Yao Z、Zeng Y、Liu C、Jin H、Wang H、Zhang Y、Ding C、Chen G
第一作者单位
Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Laboratory of Structural Immunology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.China
通讯作者单位
Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Laboratory of Structural Immunology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China. wudaichao@usc.edu.cn.China
文献类型
综述
期刊
Journal of experimental & clinical cancer research : CR2024 Sep 28
原文标识
PubMed 39342365 · DOI 10.1186/s13046-024-03195-5